Advanced Health Intelligence (MYZQF) 6-K 6 Mar 23 Current Report Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Dec. 31, 2022
Document Information Line Items
Entity Registrant Name	Advanced Health Intelligence Ltd
Document Type	6-K
Current Fiscal Year End Date	--06-30
Amendment Flag	false
Entity Central Index Key	0001815436
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity File Number	001-41089

Consolidated Statement of Profi

Consolidated Statement of Profit or Loss and Other Comprehensive Income - USD ($)	6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Profit or loss [abstract]
Software income	$ 117,504	$ 8,854
Integration and development income	240,410	132,800
Operating revenue	357,914	141,654
Other revenue	162,796	156,465
Expenses
General administration	(2,677,364)	(1,709,338)
Employee expenses	(2,181,981)	(8,609,482)
Sales and marketing	(501,944)	(1,022,829)
Impairment of assets and receivables	(229,391)	(2,266,187)
Infrastructure costs	(82,471)
NASDAQ listing expenses		(1,994,478)
Total expenses	(5,673,151)	(15,602,314)
Operating loss	(5,152,441)	(15,304,195)
Finance income	99,654	76,830
Finance costs	(62,828)	(134,970)
Net finance income / (costs)	36,826	(58,140)
Loss before income tax benefit	(5,115,615)	(15,362,335)
Income tax benefit	1,209,344	890,113
Loss after income tax benefit for the half-year attributable to the owners of Advanced Health Intelligence Ltd	(3,906,271)	(14,472,222)
Other comprehensive income
Items that may be reclassified subsequently to profit or loss	7,347	(2,280)
Foreign currency translation
Other comprehensive income for the half-year, net of tax	7,347	(2,280)
Total comprehensive income for the half-year attributable to the owners of Advanced Health Intelligence Ltd	$ (3,898,924)	$ (14,474,502)
Basic earnings per share (in Dollars per share)	$ (2.43)	$ (10.22)
Diluted earnings per share (in Dollars per share)	$ (2.43)	$ (10.22)

Consolidated Statement of finan

Consolidated Statement of financial position - USD ($)	Dec. 31, 2022	Jun. 30, 2022
Current assets
Cash and cash equivalents	$ 608,515	$ 6,011,368
Trade and other receivables	1,646,093	51,176
Prepayments	1,357,425	895,813
Total current assets	3,612,033	6,958,357
Non-current assets
Other financial assets	65,443	37,500
Right-of-use assets	400,140	35,199
Property, plant, and equipment	171,688	94,767
Investments	2,565,082	2,565,082
Intangibles	4,678,714	972,732
Total non-current assets	7,881,067	3,705,280
Total assets	11,493,100	10,663,637
Current liabilities
Trade and other payables	1,519,437	500,769
Lease liabilities	55,676	51,213
Employee benefits	618,471	383,236
Other	123,889
Current liabilities before interest bearing borrowings	2,317,473	935,218
Interest bearing borrowings	1,711,853	1,110,171
Total current liabilities	4,029,326	2,045,389
Non-current liabilities
Lease liabilities	344,464
Employee benefits	130,574	62,861
Other payables	656,928
Total non-current liabilities	1,131,966	62,861
Total liabilities	5,161,292	2,108,250
Net assets	6,331,808	8,555,387
Equity
Issued capital	71,803,404	61,822,859
Reserves	1,040,247	9,338,100
Accumulated losses	(66,511,843)	(62,605,572)
Total equity	$ 6,331,808	$ 8,555,387

Consolidated Statement of Chang

Consolidated Statement of Changes in Equity - USD ($)	Issued Capital	Equity compensation reserve	Foreign currency translation reserve	Accumulated losses	Total
Balance at Jun. 30, 2021	$ 39,213,794	$ 5,293,019		$ (42,528,729)	$ 1,978,084
Loss after income tax benefit for the half-year				(14,472,222)	(14,472,222)
Other comprehensive income for the half-year, net of tax			(2,280)		(2,280)
Total comprehensive income for the half-year			(2,280)	(14,472,222)	(14,474,502)
Transactions with owners in their capacity as owners:
Performance rights exercised	556,500	(556,500)
Options exercised	1,665,668	(490,767)			1,174,901
Ordinary shares - NASDAQ	16,674,963	31,820			16,706,783
Costs of capital raising - NASDAQ	(2,856,323)				(2,856,323)
Repayment of notes	3,125,964				3,125,964
Service providers	935,238				935,238
Employees / Directors		6,434,344			6,434,344
Balance at Dec. 31, 2021	59,315,804	10,711,916	(2,280)	(57,000,951)	13,024,489
Balance at Jun. 30, 2022	61,822,859	9,338,100		(62,605,572)	8,555,387
Loss after income tax benefit for the half-year				(3,906,271)	(3,906,271)
Other comprehensive income for the half-year, net of tax			7,347		7,347
Total comprehensive income for the half-year			7,347	(3,906,271)	(3,898,924)
Shares issued for Vertica acquisition	180,000				180,000
Shares issued for Wellteq acquisition	1,673,631				1,673,631
Capital raising	(178,286)				(178,286)
Transactions with owners in their capacity as owners:
Performance rights exercised	8,305,200	(8,305,200)
Balance at Dec. 31, 2022	$ 71,803,404	$ 1,032,900	$ 7,347	$ (66,511,843)	$ 6,331,808

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($)	6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Receipts from customers	$ 168,550	$ 188,371
Research & Development tax incentive grant		890,113
Interest received		36
Interest and other costs of finance paid	(25,939)	(54,905)
Payments to suppliers and employees	(4,516,119)	(4,471,599)
Net cash used in operating activities	(4,373,508)	(3,447,984)
Cash flows from investing activities
Payments for property, plant and equipment	(6,470)	(89,524)
Loans to other entities	(1,000,000)	(261,912)
Payments for investments	(187,300)	(2,076,826)
Payments for application development costs		(15,980)
Cash acquired from acquisition of Investee companies	343,607
Net cash used in investing activities	(850,163)	(2,444,242)
Cash flows from financing activities
Proceeds from issue of shares		16,706,783
Proceeds from exercise of options		1,174,903
Proceeds from borrowings		700,000
Share issue transaction costs	(178,250)	(2,357,284)
Repayment of borrowings		(218,047)
Repayment of lease liabilities		(40,355)
Net cash from/(used in) financing activities	(178,250)	15,966,000
Net increase/(decrease) in cash and cash equivalents	(5,401,921)	10,073,774
Cash and cash equivalents at the beginning of the financial half-year	6,011,368	2,172,499
Effects of exchange rate changes on cash and cash equivalents	(932)	39,409
Cash and cash equivalents at the end of the financial half-year	$ 608,515	$ 12,285,682

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Dec. 31, 2022
Significant Accounting Policies [Abstract]
Significant accounting policies	Note 1. Significant accounting policies Advanced Health Intelligence Ltd (the “Company”, “the parent entity” or “AHI”) is a public company domiciled in Australia and dual listed on both the Australian Securities Exchange (ASX) and the NASDAQ Capital Market in the United States of America. The consolidate financial report of the Company and its subsidiaries, together referred to as the consolidated entity. These general purpose financial statements for the interim half-year reporting period ended 31 December 2022 have been prepared in accordance with Australian Accounting Standard AASB 134 ‘Interim Financial Reporting’ and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 ‘Interim Financial Reporting’. These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2022 and any public announcements made by the Company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001. The principal accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, except for the policies stated below. Basis of preparation and Going Concern The half-year financial statements have been prepared on a historical cost basis except for derivative financial instruments which have been measured at fair value. Cost is based on the fair values of consideration given in exchange for assets. The Company is domiciled in Australia and all amounts are presented in Australian dollars. For the purpose of preparing the half-year financial statements, the half year has been treated as a discrete reporting period. The financial report has been prepared on the going concern basis which contemplates the continuity of normal business activity and the realisation of assets and the settlement of liabilities in the normal course of business. For the half-year ended 31 December 2022, the consolidated entity incurred an operating loss of $3,906,271 (2021 - $14,472,222 loss). Notwithstanding the fact the Company incurred an operating loss, and has a net cash outflow from operating activities amounting to $4,373,508, the Directors are of the opinion that the consolidated entity is a going concern for the following reasons: ● Following the Company’s successful dual listing on the NASDAQ securities exchange in the United States, the Company has gained access to larger capital markets, which as enhanced its ability to raise capital, as was evidenced by the $16.1 million before costs the Company raised from its IPO on the NASDAQ ● As stated in the Company’s Appendix 4C Quarterly Cash Flow report for entities subject to Listing Rule 4.7, as announced to the ASX on 31 January 2023, the Company is currently undertaking capital raising offers with several financing offers received. ● The consolidated entity has executed numerous agreements with channel partners across its business verticals and as such, is transitioning to a “growth” phase. The consolidated entity is in the process of expanding its operations with the recent acquisitions of South Africa based Vertica Health and the Canadian listed Wellteq Digital Health. ● It is expected that 7 of the current partners will launch with the AHI technology within their apps throughout the current financial year, subject to any unforeseen delays. The consolidated entity’s ability to continue as a going concern and meet future working capital requirements is dependent on the above points being realised. Should the Company not be successful in generating the required cash flows, there is a material uncertainty that may cast significant doubt on the Company’s ability to continue as a going concern. Business Combinations The acquisition method of accounting is used to account for business combinations regardless of whether equity instruments or other assets are acquired. The consideration transferred is the sum of the acquisition-date fair values of the assets transferred, equity instruments issued, or liabilities incurred by the acquirer to former owners of the acquiree and the amount of any non-controlling interest in the acquiree. For each business combination, the non-controlling interest in the acquiree is measured at either fair value or at the proportionate share of the acquiree’s identifiable net assets. All acquisition costs are expensed as incurred to profit or loss. On the acquisition of a business, the consolidated entity assesses the financial assets acquired and liabilities assumed for appropriate classification and designation in accordance with the contractual terms, economic conditions, the consolidated entity’s operating or accounting policies and other pertinent conditions in existence at the acquisition-date. Where the business combination is achieved in stages, the consolidated entity remeasures its previously held equity interest in the acquiree at the acquisition-date fair value and the difference between the fair value and the previous carrying amount is recognised in profit or loss. Contingent consideration to be transferred by the acquirer is recognised at the acquisition-date fair value. Subsequent changes in the fair value of the contingent consideration classified as an asset or liability is recognised in profit or loss. Contingent consideration classified as equity is not remeasured and its subsequent settlement is accounted for within equity. The difference between the acquisition-date fair value of assets acquired, liabilities assumed and any non-controlling interest in the acquiree and the fair value of the consideration transferred and the fair value of any pre-existing investment in the acquiree is recognised as goodwill. If the consideration transferred and the pre-existing fair value is less than the fair value of the identifiable net assets acquired, being a bargain purchase to the acquirer, the difference is recognised as a gain directly in profit or loss by the acquirer on the acquisition-date, but only after a reassessment of the identification and measurement of the net assets acquired, the non-controlling interest in the acquiree, if any, the consideration transferred and the acquirer’s previously held equity interest in the acquirer. Business combinations are initially accounted for on a provisional basis. The acquirer retrospectively adjusts the provisional amounts recognised and also recognises additional assets or liabilities during the measurement period, based on new information obtained about the facts and circumstances that existed at the acquisition-date. The measurement period ends on either the earlier of (i) 12 months from the date of the acquisition or (ii) when the acquirer receives all the information possible to determine fair value. Accounting policies and methods of computation The same accounting policies and methods of computation have consistently been followed in these half-year financial statements as compared with the most recent annual financial statements. Significant accounting judgements and key estimates The preparation of financial reports requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income, and expense. Actual results may differ from these estimates. The same judgments, estimates and assumptions were used in preparing the half year financial report as those used in preparing the financial report for the year ended 30 June 2022. New or amended Accounting Standards and Interpretations adopted The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (‘AASB’) that are mandatory for the current reporting period. Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

Business Combinations

Business Combinations	6 Months Ended
	Dec. 31, 2022
Disclosure Of Contingent Liabilities In Business Combination Text Block Abstract
Business combinations	Note 2. Business combinations Wellteq Acquisition On 6 December 2022, the Company acquired 100% of the ordinary shares of Wellteq Digital Health Inc (‘Wellteq’) and its wholly owned subisidiaries for the total non-cash consideration transferred of $1,673,631 on completion of the court-approved Plan of Arrangement in British Columbia, Canada. Consideration comprised 17,804,587 shares in AHI at an issue price of $0.094 per share. In conjunction with the Arrangement Agreement, AHI and Wellteq also entered into a loan agreement whereby AHI agreed to advance to wellteq up to $1,200,000. As at the time of acquisition, AHI had advanced to wellteq $1,000,000. Interest of $16,711 had accrued at the time of acquisition. The loan between AHI and Wellteq settled on business combination for $1,000,000. At acquisition, the fair value of the total consideration was $2,673,631. representing the value of the shares issued and loan settled. Wellteq was listed on the Canadian Securities Exchange (CSE: WTEQ) and is a leading provider of corporate wellness solutions developed to provide data-driven personalized health and wellness coaching to engage its users in healthier behaviours. As an enterprise (business-to-business) model Wellteq currently has two main sectors of customers, employers, and insurance companies. Due to the proximity of the acquisition to the balance date of 31 December 2022, the business combination has been accounted for on a provisional basis. Should new information obtained about the facts and circumstances that existed at the acquisition-date come to light, AHI may retrospectively adjust the provisional amounts recognised and also recognise additional assets or liabilities during the measurement period. The measurement period ends on either the earlier of (i) 12 months from the date of the acquisition or (ii) when the acquirer receives all the information possible to determine fair value. Details of the acquisition are as follows: Fair value $ Cash and cash equivalents 422,331 Trade receivables 238,866 Other current assets 109,235 Equipment 94,833 Trade payables and accrued liabilities (652,239 ) Employee benefits (49,537 ) Other provisions (180,356 ) Deferred revenue (150,016 ) Net liabilities acquired (166,883 ) Goodwill 2,840,514 Acquisition-date fair value of the total consideration transferred 2,673,631 Representing: Advanced Health Intelligence Ltd shares issued to vendor 1,673,631 Loan between AHI and Wellteq settled on business combination 1,000,000 2,673,631 Vertica Acquisition On 5 August 2022, the Company concluded a Share Sale Agreement to acquire 100% of the ordinary shares of Vertica Health (Pty) Ltd (‘Vertica’), a South African registered company, for a combination of cash and non-cash consideration. The consideration comprised cash and non-cash consideration as follows: ● 1,500,000 AHI fully paid ordinary shares issued on closing, escrowed for 24 months from issue; ● US$100,000 cash payable on transaction close; ● US$250,000 payable 1 year from closing; and ● US$250,000 payable 2 years from closing. AHI shares were valued at a market price of $0.12 per share at the time of the acquisition. The business combination has been accounted for on a provisional basis. Should new information obtained about the facts and circumstances that existed at the acquisition-date come to light, AHI may retrospectively adjust the provisional amounts recognised and also recognise additional assets or liabilities during the measurement period. The measurement period ends on either the earlier of (i) 12 months from the date of the acquisition or (ii) when the acquirer receives all the information possible to determine fair value. Details of the acquisition are as follows: Fair value $ Cash and cash equivalents 32 Trade receivables 2,616 Trade payables (2,477 ) Net assets acquired 171 Goodwill 981,176 Acquisition-date fair value of the total consideration transferred 981,347 Representing: Cash paid to vendor 144,419 Advanced Health Intelligence Ltd fully paid ordinary shares issued to vendor 180,000 Deferred cash payable to vendor 656,928 981,347

Operating Segments

Operating Segments	6 Months Ended
	Dec. 31, 2022
Operating Segments [Abstract]
Operating segments	Note 3. Operating segments The consolidated entity has identified its operating segments based on the internal reports that are reviewed and used by the Board of Directors in assessing performance and determining the allocation of resources. Reportable segments disclosed are based on aggregating operating segments, where the segments have similar characteristics. The consolidated entity’s sole activity is mobile application and technology development. Therefore, it has aggregated all operating segments into the one reportable segment being technological development.

Software Income

Software Income	6 Months Ended
	Dec. 31, 2022
Software Income [Abstract]
Software income	Note 4. Software income Consolidated 31 December 31 December 2022 2021 $ $ Software development kits - per user 34,986 8,709 Software development kits - per scan 2,032 145 Software subscriptions 80,486 - 117,504 8,854

Other Revenue

Other Revenue	6 Months Ended
	Dec. 31, 2022
Other Revenue [Abstract]
Other revenue	Note 5. Other revenue Consolidated 31 December 31 December 2022 2021 $ $ Joint venture income 67,472 96,208 Grant income 89,585 - Other income 5,739 60,257 Other revenue 162,796 156,465

Employee Expenses

Employee Expenses	6 Months Ended
	Dec. 31, 2022
Employee expenses [Abstract]
Employee expenses	Note 6. Employee expenses Consolidated 31 December 31 December 2022 2021 $ $ Salaries and wages 2,138,159 1,687,280 Superannuation contributions 214,856 165,201 Share based payments - 6,434,344 Employment taxes and insurances (200,991 ) 267,665 Other employment expenses 29,957 54,992 2,181,981 8,609,482

Trade and Other Receivables

Trade and Other Receivables	6 Months Ended
	Dec. 31, 2022
Trade and other receivables [Abstract]
Trade and other receivables	Note 7. Trade and other receivables Consolidated 31 December 30 June 2022 2022 $ $ Trade receivables 746,325 286,533 Less: Provision for doubtful debts (309,576 ) (235,357 ) 436,749 51,176 R&D tax incentive refund 1,209,344 - 1,646,093 51,176

Right-of-Use Assets

Right-of-Use Assets	6 Months Ended
	Dec. 31, 2022
Right-of-Use Assets [Abstract]
Right-of-use assets	Note 8. Right-of-use assets Consolidated 31 December 30 June 2022 2022 $ $ Land and buildings - right-of-use 400,140 105,597 Less: Accumulated depreciation - (70,398 ) 400,140 35,199 The consolidated entity had a 3-year lease agreement for office premises in Perth, Australia which ended on 31 December 2022. The consolidated entity extended its lease over the premises for an additional 3 years, with options for a 4th and 5th year. The total payments under the lease amounting to $487,469 have been discounted at the Company’s incremental borrowing rate of 7.8% in order to determine the initial lease liability of $400,140. To determine the incremental borrowing rate, third party financing was used as a starting point and adjusted to reflect changes in financing conditions.

Investments

Investments	6 Months Ended
	Dec. 31, 2022
Investments [Abstract]
Investments	Note 9. Investments The recoverable amounts of the Company’s investments are reviewed at each reporting date. As the Company’s investments are in unlisted entities, the determination of recoverable value is subject to various estimates and assumptions. As an accurate assessment of recoverable value is not available at the reporting date, the Company has elected to continue with provisions for impairment against each of its investments, as shown in the table below. When the Company can make a more accurate determination of recoverable value, the Company will re-assess whether a provision for impairment is still required for its investments. Consolidated 31 December 30 June 2022 2022 $ $ Investment in Triage Technologies Inc 2,565,082 2,565,082 Body Triage Jana Composition Technologies Care Technologies $ $ $ Balance at 1 July 2021 1,362,717 690,153 680,008 Additional Investment 3,126,950 - - Interest and other costs - 83,031 16,771 Foreign exchange movement (10,779 ) (20,903 ) - Provision for impairment (1,913,806 ) (752,281 ) (696,779 ) - - - Balance at 30 June 2022 2,565,082 - - Balance at 31 December 2022 2,565,082 - -

Intangibles

Intangibles	6 Months Ended
	Dec. 31, 2022
Intangibles [Abstract]
Intangibles	Note 10. Intangibles Consolidated 31 December 30 June 2022 2022 $ $ Goodwill - at cost 3,821,690 - Development - at cost 851,555 - Less: Accumulated amortisation (28,727 ) - Less: Impairment (816,944 ) - 5,884 - Application development - at cost 1,317,542 1,317,542 Less: Accumulated amortisation (870,358 ) (806,474 ) 447,184 511,068 Development - new capabilities - at cost 227,682 227,682 Less: Accumulated amortisation (84,243 ) (63,751 ) 143,439 163,931 Development - enhancements - at cost 77,128 77,128 Less: Accumulated amortisation (28,537 ) (21,596 ) 48,591 55,532 Development - research - at cost 336,390 336,390 Less: Accumulated amortisation (124,464 ) (94,189 ) 211,926 242,201 4,678,714 972,732

Lease Liabilities

Lease Liabilities	6 Months Ended
	Dec. 31, 2022
Lease Liabilities [Abstract]
Lease liabilities	Note 11. Lease liabilities Consolidated 31 December 30 June 2022 2022 $ $ Current liability 55,676 51,213 Non-current liability 344,464 - 400,140 51,213 The consolidated entity had a 3-year lease agreement for office premises in Perth, Australia which ended on 31 December 2022. The total payments under the lease amounting to $299,129 were discounted at the Company’s incremental borrowing rate of 10% in order to determine the initial lease liability of $211,191. To determine the incremental borrowing rate, third- party financing received was used as a starting point and adjusted to reflect changes in financing conditions since the third- party financing was received. The consolidated entity extended its lease over the premises for an additional 3 years, with options for a 4th and 5th year. The total payments under the lease amounting to $487,469 have been discounted at the Company’s incremental borrowing rate of 7.8% in order to determine the initial lease liability of $400,140. To determine the incremental borrowing rate, third party financing was used as a starting point and adjusted to reflect changes in financing conditions.

Employee Benefits

Employee Benefits	6 Months Ended
	Dec. 31, 2022
Employee benefits [Abstract]
Employee benefits	Note 12. Employee benefits Consolidated 31 December 30 June 2022 2022 Current $ $ Long service leave 36,746 - Employee benefits 581,725 383,236 618,471 383,236 Consolidated 31 December 30 June 2022 2022 Non-current $ $ Long service leave 130,574 62,861

Other

Other	6 Months Ended
	Dec. 31, 2022
Other [Abstract]
Other	Note 13. Other Consolidated 31 December 30 June 2022 2022 $ $ Deferred revenue 123,889 -

Interest Bearing Borrowings

Interest Bearing Borrowings	6 Months Ended
	Dec. 31, 2022
Interest bearing borrowings [Abstract]
Interest bearing borrowings	Note 14. Interest bearing borrowings Consolidated 31 December 30 June 2022 2022 $ $ R&D prepayment loan (1) 700,000 700,000 Other loans (2) 1,011,853 410,171 1,711,853 1,110,171 (1) The Company received a $700,000 R&D tax prepayment loan from R&D Capital Partners Pty Ltd. The loan attracts interest at a rate of 1.15% per month and was repaid in full on 30 January 2023 following the assessment of AHI’s 2022 R&D tax incentive. (2) Other loans are unsecured and interest bearing.

Other Payables

Other Payables	6 Months Ended
	Dec. 31, 2022
Other Payables [Abstract]
Other payables	Note 15. Other payables Consolidated 31 December 30 June 2022 2022 $ $ Deferred acquisition consideration 656,928 - The deferred acquisition consideration relates to the acquisition of Vertica Health (Pty) Ltd. Refer to Note 2.

Issued Capital

Issued Capital	6 Months Ended
	Dec. 31, 2022
Issued Capital [Abstract]
Issued capital	Note 16. Issued capital Ordinary shares Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the Company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the Company does not have a limited amount of authorised capital. On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote. There are no externally imposed capital requirements. Consolidated 31 December 30 June 31 December 30 June 2022 2022 2022 2022 Shares Shares $ $ Issued Capital Ordinary 196,053,969 166,749,382 71,803,404 61,822,859 31 December 30 June 31 December 30 June 2022 2022 2022 2022 Share movements during the period - ordinary shares Shares Shares $ $ At the start of the period 166,749,382 136,362,538 61,822,859 39,213,794 Shares issued on exercise of Performance rights 10,000,000 5,000,000 8,305,200 1,996,500 Shares issued on exercise of Options - 3,103,622 - 1,665,905 Shares issued to related party - 2,000,000 - 920,000 Share based payments - 1,172,812 - 1,050,237 Share issue - NASDAQ IPO - 16,100,000 - 16,706,786 Share issue - conversion of convertible note - 3,010,410 - 3,125,964 Share issue - Vertica acquisition 1,500,000 - 180,000 - Share issue - Wellteq acquisition 17,804,587 - 1,673,631 - Less share issue costs - - (178,286 ) (2,856,327 ) 196,053,969 166,749,382 71,803,404 61,822,859

Reserves

Reserves	6 Months Ended
	Dec. 31, 2022
Reserves [Abstract]
Reserves	Note 17. Reserves Consolidated 31 December 30 June 2022 2022 $ $ Equity Remuneration Reserve 1,032,900 9,338,100 Foreign currency reserve 7,347 - 1,040,247 9,338,100 Equity compensation reserve The reserve is used to recognise the value of equity benefits provided to employees and Directors as part of their remuneration, and other parties as part of their compensation for services. Consolidated 31 December 30 June 2022 2022 Movement in equity compensation reserve $ $ Balance at the beginning of the year 9,338,100 5,293,019 Fair value vesting expense of options and performance rights - 6,532,583 Fair value of options/performance rights exercised during the year (8,305,200 ) (2,487,502 ) Balance at the end of the period 1,032,900 9,338,100 Foreign currency reserve The reserve is used to recognise exchange differences arising from the translation of the financial statements of foreign operations to Australian dollars. It is also used to recognise gains and losses on hedges of the net investments in foreign operations. Consolidated 31 December 30 June 2022 2022 Movement in foreign currency reserve $ $ Balance at the beginning of the period - - Movement in the value of foreign subsidiary losses and intercompany loan balances 7,347 - Balance at the end of the period 7,347 -

Dividends

Dividends	6 Months Ended
	Dec. 31, 2022
Dividends [Abstract]
Dividends	Note 18. Dividends There were no dividends paid, recommended, or declared during the current or previous financial half-year. There are no franking credits available as at 31 December 2022.

Contingencies

Contingencies	6 Months Ended
	Dec. 31, 2022
Contingencies [Abstract]
Contingencies	Note 19. Contingencies There are no material contingent assets or liabilities at the reporting date.

Commitments

Commitments	6 Months Ended
	Dec. 31, 2022
Commitments [Abstract]
Commitments	Note 20. Commitments Lease commitments The company has a lease for its principal place of business at Unit 5, 71-73 South Perth Esplanade, South Perth in Western Australia (Lease), which was initially entered into on 1 January 2020 and renewed for a further term commencing 1 January 2023. The lease is accounted for under accounting standard AASB 16 Leases. Refer to Note 11. Other commitments (i) During the year ended 30 June 2022, AHI completed its investment of USD $3,000,000 in Triage Technologies, Inc. (“Triage”) However, AHI has, by mutual agreement with Triage, yet to issue it with USD $3,000,000 in ordinary shares in AHI, as part of a strategic plan to expand the Company’s service offering, referred to as “DermaScan”. (ii) As disclosed in AHI’s 2022 Annual report, AHI has an Agreement with Tinjoy Biotech Limited “Tinjoy”), to contribute USD $200,000 towards Tinjoy’s marketing costs, and has an option to invest in Tinjoy’s Winscan Platform as follows: ● AHI has the right to acquire up to 40% of Tinjoy’s Winscan Platform, priced at a valuation of US$10 million taking for consideration to be approximately US$2-4 million. This can be in cash or shares in AHI or a combination as mutually agreed. ● 12-24 month option to take up the 40% at AHI’s option to acquire a holding in WinScan. The option would be triggered should WinScan achieve user numbers of 5 million users a month. This would trigger a 20% investment of US$2 million from AHI. ● If WinScan achieves a user base of 10 million monthly users, AHI would be required to take up a 40% stake in WinScan at an agreed investment of US$4 million. ● In the event AHI exercises its option, the US$200,000 marketing and training advance will form part of the total investment outlined above. ● At the date of this report, US$50,000 in payments have been made to Tinjoy in lieu of AHI’s marketing contribution. To the date of this report, AHI has paid US$150,000 to Tinjoy, with a remaining balance of US$50,000 committed, but not yet paid.

Events after the reporting peri

Events after the reporting period	6 Months Ended
	Dec. 31, 2022
Events after the reporting period [Abstract]
Events after the reporting period	Note 21. Events after the reporting period Upvio Healthtech agreement On 25 January 2023, AHI announced that it had concluded formal agreements with Upvio Healthtech. Upvio is a healthcare technology company that builds software designed to empower medical, health and wellness professionals to tech-enable and adopt ground-breaking tech-tools that redefine hybrid, virtual and remote care. These features include human imaging, feature rich appointment scheduling, digital forms, video calls, virtual waiting rooms, asynchronous and synchronous chat, a patient portal, and the ability to integrate into any existing software. Upvio enables geocloud storage for securely storing sensitive patient information, ensuring that patients’ data is always kept safe and secure. Upvio aims to be the first telehealth platform in the world with in-built contactless human imaging tools that can provide a scientifically validated health risk assessment in real-time. This is a game-changing development, as it means that healthcare professionals can now obtain an accurate picture of a patient’s health and risk status more easily, conveniently, and affordably without the need for physical contact, drastically reducing the risk of malpractice. The platform is built on a digital-first ethos, with both patients and healthcare professionals in mind and brings together the best-of-breed technologies, including AHI’s scanning and risk assessment capabilities. R&D Tax offset receipt and new loan facility As announced on 30 January 2023, AHI informed shareholders that the consolidated entity had received an R&D Grant payment of $1,209,334 from the Australian Tax Office. In addition to the R&D Grant funding payment, AHI has secured a $1,000,000 short term loan facility to bolster its cash position. AHI is currently negotiating funding offers it has received from a number of parties. The facility, along with the R&D Grant funding received gives AHI time to evaluate and the finalise funding offers it has received. The loan facility was entered into an entity associated with Mr Peter Wall (‘lender’), under which $1 million has been drawn down by AHI for working capital purposes. No interest is payable on the facility, provided the amount drawn down from the facility is fully repaid by 15 March 2023 (maturity date). If the amount drawn down from the facility is not repaid by the maturity date, interest at the rate of 15% per annum will be applied on the amount owing until the outstanding amount is fully repaid. In lieu of no interest being payable on amount drawn down from the facility, the Company has agreed to allot and issue 500,000 fully paid ordinary shares to the lender. Upon receipt of its R&D Grant funding, AHI has since repaid the lender $400,000 of the funds advanced on 31 January 2023. Augmented Reality Concierge agreement On 14 February 2023, AHI announced the signing of a Master Services Agreement (MSA) with US-based Augmented Reality Concierge, LLC (‘ARC’). ARC is a unique company that builds and implements state-of-the-art applications that empower consumers and companies to simplify and enhance their surroundings whilst improving the lives of their consumers. Using the latest proprietary, innovative technologies, The ARC’s creative tools are fun and exciting, allowing people to engage with them to realize their goals. The ARC was created in 2019 to build a fitness application that uses augmented reality navigation to guide users in the gym and show them what to do and how to do it based on each gym’s specific equipment range. During this time, the ARC realized that the technology would solve similar problems confronting universities, airports, malls, grocery stores, and theme parks, to mention a few. The ARC then went a step further and designed a true “concierge” concept that caters to any wants or needs of a company or its consumer. AHI and ARC have executed a standard AHI MSA, which entails the legal and contractual terms in which AHI agrees to grant the ARC the right to use AHI’s licensed Software Development Kits (SDKs) and related intellectual property once integrated into the ARC application/platform. No other matter or circumstance has arisen since 31 December 2022 that has significantly affected, or may significantly affect the consolidated entity’s operations, the results of those operations, or the consolidated entity’s state of affairs in future financial years.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of preparation and Going Concern	Basis of preparation and Going Concern The half-year financial statements have been prepared on a historical cost basis except for derivative financial instruments which have been measured at fair value. Cost is based on the fair values of consideration given in exchange for assets. The Company is domiciled in Australia and all amounts are presented in Australian dollars. For the purpose of preparing the half-year financial statements, the half year has been treated as a discrete reporting period. The financial report has been prepared on the going concern basis which contemplates the continuity of normal business activity and the realisation of assets and the settlement of liabilities in the normal course of business. For the half-year ended 31 December 2022, the consolidated entity incurred an operating loss of $3,906,271 (2021 - $14,472,222 loss). Notwithstanding the fact the Company incurred an operating loss, and has a net cash outflow from operating activities amounting to $4,373,508, the Directors are of the opinion that the consolidated entity is a going concern for the following reasons: ● Following the Company’s successful dual listing on the NASDAQ securities exchange in the United States, the Company has gained access to larger capital markets, which as enhanced its ability to raise capital, as was evidenced by the $16.1 million before costs the Company raised from its IPO on the NASDAQ ● As stated in the Company’s Appendix 4C Quarterly Cash Flow report for entities subject to Listing Rule 4.7, as announced to the ASX on 31 January 2023, the Company is currently undertaking capital raising offers with several financing offers received. ● The consolidated entity has executed numerous agreements with channel partners across its business verticals and as such, is transitioning to a “growth” phase. The consolidated entity is in the process of expanding its operations with the recent acquisitions of South Africa based Vertica Health and the Canadian listed Wellteq Digital Health. ● It is expected that 7 of the current partners will launch with the AHI technology within their apps throughout the current financial year, subject to any unforeseen delays. The consolidated entity’s ability to continue as a going concern and meet future working capital requirements is dependent on the above points being realised. Should the Company not be successful in generating the required cash flows, there is a material uncertainty that may cast significant doubt on the Company’s ability to continue as a going concern.
Business Combinations	Business Combinations The acquisition method of accounting is used to account for business combinations regardless of whether equity instruments or other assets are acquired. The consideration transferred is the sum of the acquisition-date fair values of the assets transferred, equity instruments issued, or liabilities incurred by the acquirer to former owners of the acquiree and the amount of any non-controlling interest in the acquiree. For each business combination, the non-controlling interest in the acquiree is measured at either fair value or at the proportionate share of the acquiree’s identifiable net assets. All acquisition costs are expensed as incurred to profit or loss. On the acquisition of a business, the consolidated entity assesses the financial assets acquired and liabilities assumed for appropriate classification and designation in accordance with the contractual terms, economic conditions, the consolidated entity’s operating or accounting policies and other pertinent conditions in existence at the acquisition-date. Where the business combination is achieved in stages, the consolidated entity remeasures its previously held equity interest in the acquiree at the acquisition-date fair value and the difference between the fair value and the previous carrying amount is recognised in profit or loss. Contingent consideration to be transferred by the acquirer is recognised at the acquisition-date fair value. Subsequent changes in the fair value of the contingent consideration classified as an asset or liability is recognised in profit or loss. Contingent consideration classified as equity is not remeasured and its subsequent settlement is accounted for within equity. The difference between the acquisition-date fair value of assets acquired, liabilities assumed and any non-controlling interest in the acquiree and the fair value of the consideration transferred and the fair value of any pre-existing investment in the acquiree is recognised as goodwill. If the consideration transferred and the pre-existing fair value is less than the fair value of the identifiable net assets acquired, being a bargain purchase to the acquirer, the difference is recognised as a gain directly in profit or loss by the acquirer on the acquisition-date, but only after a reassessment of the identification and measurement of the net assets acquired, the non-controlling interest in the acquiree, if any, the consideration transferred and the acquirer’s previously held equity interest in the acquirer. Business combinations are initially accounted for on a provisional basis. The acquirer retrospectively adjusts the provisional amounts recognised and also recognises additional assets or liabilities during the measurement period, based on new information obtained about the facts and circumstances that existed at the acquisition-date. The measurement period ends on either the earlier of (i) 12 months from the date of the acquisition or (ii) when the acquirer receives all the information possible to determine fair value.
Accounting policies and methods of computation	Accounting policies and methods of computation The same accounting policies and methods of computation have consistently been followed in these half-year financial statements as compared with the most recent annual financial statements.
Significant accounting judgements and key estimates	Significant accounting judgements and key estimates The preparation of financial reports requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income, and expense. Actual results may differ from these estimates. The same judgments, estimates and assumptions were used in preparing the half year financial report as those used in preparing the financial report for the year ended 30 June 2022.
New or amended Accounting Standards and Interpretations adopted	New or amended Accounting Standards and Interpretations adopted The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (‘AASB’) that are mandatory for the current reporting period. Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

Business Combinations (Tables)

Business Combinations (Tables)	6 Months Ended
	Dec. 31, 2022
Disclosure Of Contingent Liabilities In Business Combination Text Block Abstract
Schedule of acquisition	Fair value $ Cash and cash equivalents 422,331 Trade receivables 238,866 Other current assets 109,235 Equipment 94,833 Trade payables and accrued liabilities (652,239 ) Employee benefits (49,537 ) Other provisions (180,356 ) Deferred revenue (150,016 ) Net liabilities acquired (166,883 ) Goodwill 2,840,514 Acquisition-date fair value of the total consideration transferred 2,673,631 Representing: Advanced Health Intelligence Ltd shares issued to vendor 1,673,631 Loan between AHI and Wellteq settled on business combination 1,000,000 2,673,631 Fair value $ Cash and cash equivalents 32 Trade receivables 2,616 Trade payables (2,477 ) Net assets acquired 171 Goodwill 981,176 Acquisition-date fair value of the total consideration transferred 981,347 Representing: Cash paid to vendor 144,419 Advanced Health Intelligence Ltd fully paid ordinary shares issued to vendor 180,000 Deferred cash payable to vendor 656,928 981,347

Software Income (Tables)

Software Income (Tables)	6 Months Ended
	Dec. 31, 2022
Software Income [Abstract]
Schedule of software development	Consolidated 31 December 31 December 2022 2021 $ $ Software development kits - per user 34,986 8,709 Software development kits - per scan 2,032 145 Software subscriptions 80,486 - 117,504 8,854

Other Revenue (Tables)

Other Revenue (Tables)	6 Months Ended
	Dec. 31, 2022
Other Revenue [Abstract]
Schedule of other revenue	Consolidated 31 December 31 December 2022 2021 $ $ Joint venture income 67,472 96,208 Grant income 89,585 - Other income 5,739 60,257 Other revenue 162,796 156,465

Employee Expenses (Tables)

Employee Expenses (Tables)	6 Months Ended
	Dec. 31, 2022
Employee expenses [Abstract]
Schedule of employee expenses	Consolidated 31 December 31 December 2022 2021 $ $ Salaries and wages 2,138,159 1,687,280 Superannuation contributions 214,856 165,201 Share based payments - 6,434,344 Employment taxes and insurances (200,991 ) 267,665 Other employment expenses 29,957 54,992 2,181,981 8,609,482

Trade and Other Receivables (Ta

Trade and Other Receivables (Tables)	6 Months Ended
	Dec. 31, 2022
Trade and other receivables [Abstract]
Schedule of trade and other receivables	Consolidated 31 December 30 June 2022 2022 $ $ Trade receivables 746,325 286,533 Less: Provision for doubtful debts (309,576 ) (235,357 ) 436,749 51,176 R&D tax incentive refund 1,209,344 - 1,646,093 51,176

Right-of-Use Assets (Tables)

Right-of-Use Assets (Tables)	6 Months Ended
	Dec. 31, 2022
Right-of-Use Assets [Abstract]
Schedule of right-of-use assets	Consolidated 31 December 30 June 2022 2022 $ $ Land and buildings - right-of-use 400,140 105,597 Less: Accumulated depreciation - (70,398 ) 400,140 35,199

Investments (Tables)

Investments (Tables)	6 Months Ended
	Dec. 31, 2022
Investments [Abstract]
Schedule of provision for impairment is still required for its investments	Consolidated 31 December 30 June 2022 2022 $ $ Investment in Triage Technologies Inc 2,565,082 2,565,082
Schedule of recoverable amount of the company’s investments is reviewed at each reporting date	Body Triage Jana Composition Technologies Care Technologies $ $ $ Balance at 1 July 2021 1,362,717 690,153 680,008 Additional Investment 3,126,950 - - Interest and other costs - 83,031 16,771 Foreign exchange movement (10,779 ) (20,903 ) - Provision for impairment (1,913,806 ) (752,281 ) (696,779 ) - - - Balance at 30 June 2022 2,565,082 - - Balance at 31 December 2022 2,565,082 - -

Intangibles (Tables)

Intangibles (Tables)	6 Months Ended
	Dec. 31, 2022
Intangibles [Abstract]
Schedule of Intangibles	Consolidated 31 December 30 June 2022 2022 $ $ Goodwill - at cost 3,821,690 - Development - at cost 851,555 - Less: Accumulated amortisation (28,727 ) - Less: Impairment (816,944 ) - 5,884 - Application development - at cost 1,317,542 1,317,542 Less: Accumulated amortisation (870,358 ) (806,474 ) 447,184 511,068 Development - new capabilities - at cost 227,682 227,682 Less: Accumulated amortisation (84,243 ) (63,751 ) 143,439 163,931 Development - enhancements - at cost 77,128 77,128 Less: Accumulated amortisation (28,537 ) (21,596 ) 48,591 55,532 Development - research - at cost 336,390 336,390 Less: Accumulated amortisation (124,464 ) (94,189 ) 211,926 242,201 4,678,714 972,732

Lease Liabilities (Tables)

Lease Liabilities (Tables)	6 Months Ended
	Dec. 31, 2022
Lease Liabilities [Abstract]
Schedule of lease liabilities	Consolidated 31 December 30 June 2022 2022 $ $ Current liability 55,676 51,213 Non-current liability 344,464 - 400,140 51,213

Employee Benefits (Tables)

Employee Benefits (Tables)	6 Months Ended
	Dec. 31, 2022
Disclosure Of Employee Benefits Text Block [Abstract]
Schedule of employee benefits	Consolidated 31 December 30 June 2022 2022 Current $ $ Long service leave 36,746 - Employee benefits 581,725 383,236 618,471 383,236 Consolidated 31 December 30 June 2022 2022 Non-current $ $ Long service leave 130,574 62,861

Other (Tables)

Other (Tables)	6 Months Ended
	Dec. 31, 2022
Other [Abstract]
Schedule of other	Consolidated 31 December 30 June 2022 2022 $ $ Deferred revenue 123,889 -

Interest Bearing Borrowings (Ta

Interest Bearing Borrowings (Tables)	6 Months Ended
	Dec. 31, 2022
Interest bearing borrowings [Abstract]
Schedule of interest bearing borrowings	Consolidated 31 December 30 June 2022 2022 $ $ R&D prepayment loan (1) 700,000 700,000 Other loans (2) 1,011,853 410,171 1,711,853 1,110,171 (1) The Company received a $700,000 R&D tax prepayment loan from R&D Capital Partners Pty Ltd. The loan attracts interest at a rate of 1.15% per month and was repaid in full on 30 January 2023 following the assessment of AHI’s 2022 R&D tax incentive. (2) Other loans are unsecured and interest bearing.

Other Payables (Tables)

Other Payables (Tables)	6 Months Ended
	Dec. 31, 2022
Other Payables [Abstract]
Schedule of other payables	Consolidated 31 December 30 June 2022 2022 $ $ Deferred acquisition consideration 656,928 -

Issued Capital (Tables)

Issued Capital (Tables)	6 Months Ended
	Dec. 31, 2022
Issued Capital [Abstract]
Schedule of issued capital	Consolidated 31 December 30 June 31 December 30 June 2022 2022 2022 2022 Shares Shares $ $ Issued Capital Ordinary 196,053,969 166,749,382 71,803,404 61,822,859
Schedule of ordinary share	31 December 30 June 31 December 30 June 2022 2022 2022 2022 Share movements during the period - ordinary shares Shares Shares $ $ At the start of the period 166,749,382 136,362,538 61,822,859 39,213,794 Shares issued on exercise of Performance rights 10,000,000 5,000,000 8,305,200 1,996,500 Shares issued on exercise of Options - 3,103,622 - 1,665,905 Shares issued to related party - 2,000,000 - 920,000 Share based payments - 1,172,812 - 1,050,237 Share issue - NASDAQ IPO - 16,100,000 - 16,706,786 Share issue - conversion of convertible note - 3,010,410 - 3,125,964 Share issue - Vertica acquisition 1,500,000 - 180,000 - Share issue - Wellteq acquisition 17,804,587 - 1,673,631 - Less share issue costs - - (178,286 ) (2,856,327 ) 196,053,969 166,749,382 71,803,404 61,822,859

Reserves (Tables)

Reserves (Tables)	6 Months Ended
	Dec. 31, 2022
Reserves [Abstract]
Schedule of reserves	Consolidated 31 December 30 June 2022 2022 $ $ Equity Remuneration Reserve 1,032,900 9,338,100 Foreign currency reserve 7,347 - 1,040,247 9,338,100
Schedule of equity compensation reserve	Consolidated 31 December 30 June 2022 2022 Movement in equity compensation reserve $ $ Balance at the beginning of the year 9,338,100 5,293,019 Fair value vesting expense of options and performance rights - 6,532,583 Fair value of options/performance rights exercised during the year (8,305,200 ) (2,487,502 ) Balance at the end of the period 1,032,900 9,338,100
Schedule of foreign currency reserve	Consolidated 31 December 30 June 2022 2022 Movement in foreign currency reserve $ $ Balance at the beginning of the period - - Movement in the value of foreign subsidiary losses and intercompany loan balances 7,347 - Balance at the end of the period 7,347 -

Significant Accounting Polici_2

Significant Accounting Policies (Details) - USD ($)	6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Significant Accounting Policies Text Block Abstract
Operating loss	$ 3,906,271	$ 14,472,222
Amount of operating activities	4,373,508
Capital amount	$ 16,100,000

Business Combinations (Details)

Business Combinations (Details) - USD ($)	Dec. 06, 2022	Aug. 05, 2022
Business Combinations (Details) [Line Items]
Payable		$ 250,000
Wellteq Acquisition [Member]
Business Combinations (Details) [Line Items]
Percentage of acquired ordinary shares	100%
Total non-cash consideration	$ 1,673,631
Shares issued (in Shares)	17,804,587
Shares issued price (in Dollars per share)	$ 0.094
Description of business combinations	In conjunction with the Arrangement Agreement, AHI and Wellteq also entered into a loan agreement whereby AHI agreed to advance to wellteq up to $1,200,000. As at the time of acquisition, AHI had advanced to wellteq $1,000,000. Interest of $16,711 had accrued at the time of acquisition. The loan between AHI and Wellteq settled on business combination for $1,000,000. At acquisition, the fair value of the total consideration was $2,673,631. representing the value of the shares issued and loan settled.
Vertica Health (Pty) Ltd [Member]
Business Combinations (Details) [Line Items]
Percentage of acquired ordinary shares		100%
Shares issued (in Shares)		1,500,000
Cash payable		$ 100,000
Payable		$ 250,000
Market price (in Dollars per share)		$ 0.12

Business Combinations (Detail_2

Business Combinations (Details) - Schedule of acquisition	Dec. 31, 2022 USD ($)
Wellteq Acquisition [Member]
Business Combinations (Details) - Schedule of acquisition [Line Items]
Cash and cash equivalents	$ 422,331
Trade receivables	238,866
Other current assets	109,235
Equipment	94,833
Trade payables	(652,239)
Employee benefits	(49,537)
Other provisions	(180,356)
Deferred revenue	(150,016)
Net liabilities acquired	(166,883)
Goodwill	2,840,514
Acquisition-date fair value of the total consideration transferred	2,673,631
Representing:
Advanced Health Intelligence Ltd shares issued to vendor	1,673,631
Loan between AHI and Wellteq settled on business combination	1,000,000
Total	2,673,631
Vertica Health (Pty) Ltd [Member]
Business Combinations (Details) - Schedule of acquisition [Line Items]
Cash and cash equivalents	32
Trade receivables	2,616
Trade payables	(2,477)
Net assets acquired	171
Goodwill	981,176
Acquisition-date fair value of the total consideration transferred	981,347
Representing:
Cash paid to vendor	144,419
Advanced Health Intelligence Ltd fully paid ordinary shares issued to vendor	180,000
Deferred cash payable to vendor	656,928
Representing:
Total	$ 981,347

Software Income (Details) - Sch

Software Income (Details) - Schedule of software development - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Software Income (Details) - Schedule of software development [Line Items]
Software development	$ 117,504	$ 8,854
Software Development Kits Per User [Member]
Software Income (Details) - Schedule of software development [Line Items]
Software development	34,986	8,709
Software Development Kits Per Scan [Member]
Software Income (Details) - Schedule of software development [Line Items]
Software development	2,032	145
Software subscriptions [Member]
Software Income (Details) - Schedule of software development [Line Items]
Software development	$ 80,486

Other Revenue (Details) - Sched

Other Revenue (Details) - Schedule of other revenue - USD ($)	6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule of Other Revenue [Abstract]
Joint venture income	$ 67,472	$ 96,208
Grant income	89,585
Other income	5,739	60,257
Other revenue	$ 162,796	$ 156,465

Employee Expenses (Details) - S

Employee Expenses (Details) - Schedule of employee expenses - USD ($)	6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Employee Expenses Abstract
Salaries and wages	$ 2,138,159	$ 1,687,280
Superannuation contributions	214,856	165,201
Share based payments		6,434,344
Employment taxes and insurances	(200,991)	267,665
Other employment expenses	29,957	54,992
Total employee expenses	$ 2,181,981	$ 8,609,482

Trade and Other Receivables (De

Trade and Other Receivables (Details) - Schedule of trade and other receivables - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
Schedule of Trade and Other Receivables [Abstract]
Trade receivables	$ 746,325	$ 286,533
Less: Provision for doubtful debts	(309,576)	(235,357)
Total trade receivables	436,749	51,176
R&D tax incentive refund	1,209,344
Trade and other receivables	$ 1,646,093	$ 51,176

Right-of-Use Assets (Details)

Right-of-Use Assets (Details)	6 Months Ended
	Dec. 31, 2022 USD ($)
Disclosure of quantitative information about leases for lessee [abstract]
Lease amount	$ 487,469
Incremental borrowing rate	7.80%
Initial lease liability	$ 400,140

Right-of-Use Assets (Details) -

Right-of-Use Assets (Details) - Schedule of right-of-use assets - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
Schedule Of Right Of Use Assets Abstract
Land and buildings - right-of-use	$ 400,140	$ 105,597
Less: Accumulated depreciation		(70,398)
Total	$ 400,140	$ 35,199

Investments (Details) - Schedul

Investments (Details) - Schedule of provision for impairment is still required for its investments - USD ($)	Dec. 31, 2022	Jun. 30, 2022
Schedule of Provision for Impairment is Still Required for its Investments [Abstract]
Investment in Triage Technologies Inc	$ 2,565,082	$ 2,565,082

Investments (Details) - Sched_2

Investments (Details) - Schedule of recoverable amount of the company’s investments is reviewed at each reporting date - USD ($)	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2022
Triage Technologies [Member]
Investments (Details) - Schedule of recoverable amount of the company’s investments is reviewed at each reporting date [Line Items]
Balance	$ 1,362,717
Additional Investment	3,126,950
Interest and other costs
Foreign exchange movement	(10,779)
Provision for impairment	(1,913,806)
Balance	2,565,082
Balance at 31 December 2022	2,565,082	$ 2,565,082
Jana Care [Member]
Investments (Details) - Schedule of recoverable amount of the company’s investments is reviewed at each reporting date [Line Items]
Balance	690,153
Additional Investment
Interest and other costs	83,031
Foreign exchange movement	(20,903)
Provision for impairment	(752,281)
Balance
Balance at 31 December 2022
Body Composition Technologies [Member]
Investments (Details) - Schedule of recoverable amount of the company’s investments is reviewed at each reporting date [Line Items]
Balance	680,008
Additional Investment
Interest and other costs	16,771
Foreign exchange movement
Provision for impairment	(696,779)
Balance
Balance at 31 December 2022

Intangibles (Details) - Schedul

Intangibles (Details) - Schedule of Intangibles - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
Intangibles (Details) - Schedule of Intangibles [Line Items]
Goodwill - at cost	$ 3,821,690
Intangible assets net	4,678,714	972,732
Development - at cost [Member]
Intangibles (Details) - Schedule of Intangibles [Line Items]
Development - at cost	851,555
Less: Accumulated amortisation	(28,727)
Less: Impairment	(816,944)
Total	5,884
Application development - at cost [Member]
Intangibles (Details) - Schedule of Intangibles [Line Items]
Development - at cost	1,317,542	1,317,542
Less: Accumulated amortisation	(870,358)	(806,474)
Total	447,184	511,068
Development - new capabilities - at cost [Member]
Intangibles (Details) - Schedule of Intangibles [Line Items]
Development - at cost	227,682	227,682
Less: Accumulated amortisation	(84,243)	(63,751)
Total	143,439	163,931
Development - enhancements - at cost [Member]
Intangibles (Details) - Schedule of Intangibles [Line Items]
Development - at cost	77,128	77,128
Less: Accumulated amortisation	(28,537)	(21,596)
Total	48,591	55,532
Development - research - at cost [Member]
Intangibles (Details) - Schedule of Intangibles [Line Items]
Development - at cost	336,390	336,390
Less: Accumulated amortisation	(124,464)	(94,189)
Total	$ 211,926	$ 242,201

Lease Liabilities (Details)

Lease Liabilities (Details)	6 Months Ended
	Dec. 31, 2022 USD ($)
Lease Liabilities [Abstract]
Lease agreement year	3 years
Lease amounting	$ 299,129
Incremental borrowing rate	10%
Initial lease liability	$ 211,191
Financial position, description	The consolidated entity extended its lease over the premises for an additional 3 years, with options for a 4th and 5th year
Total payments under lease amounting	$ 487,469
Incremental borrowing rate	7.80%
Initial lease liability	$ 400,140

Lease Liabilities (Details) - S

Lease Liabilities (Details) - Schedule of lease liabilities - USD ($)	Dec. 31, 2022	Jun. 30, 2022
Schedule of Lease Liabilities [Abstract]
Current liability	$ 55,676	$ 51,213
Non-current liability	344,464
Total liability	$ 400,140	$ 51,213

Employee Benefits (Details) - S

Employee Benefits (Details) - Schedule of employee benefits - USD ($)	Dec. 31, 2022	Jun. 30, 2022
Employee Benefits (Details) - Schedule of employee benefits [Line Items]
Long service leave current	$ 618,471	$ 383,236
Long term service leave current [Member]
Employee Benefits (Details) - Schedule of employee benefits [Line Items]
Long service leave current	36,746
Employee benefits [Member]
Employee Benefits (Details) - Schedule of employee benefits [Line Items]
Long service leave current	581,725	383,236
Long service leave non-current [Member]
Employee Benefits (Details) - Schedule of employee benefits [Line Items]
Long service leave non-current	$ 130,574	$ 62,861

Other (Details) - Schedule of o

Other (Details) - Schedule of other - USD ($)	Dec. 31, 2022	Jun. 30, 2022
Schedule of Other [Abstract]
Deferred revenue	$ 123,889

Interest Bearing Borrowings (De

Interest Bearing Borrowings (Details)	6 Months Ended
	Dec. 31, 2022 USD ($)
Interest bearing borrowings [Abstract]
Tax prepayment loan	$ 700,000
Loan interest at a rate	1.15%

Interest Bearing Borrowings (_2

Interest Bearing Borrowings (Details) - Schedule of interest bearing borrowings - USD ($)		Dec. 31, 2022	Jun. 30, 2022
Schedule Of Interest Bearing Borrowings Abstract
R&D prepayment loan	[1]	$ 700,000	$ 700,000
Other loans	[2]	1,011,853	410,171
Total interest bearing borrowings		$ 1,711,853	$ 1,110,171
[1]The Company received a $700,000 R&D tax prepayment loan from R&D Capital Partners Pty Ltd. The loan attracts interest at a rate of 1.15% per month and was repaid in full on 30 January 2023 following the assessment of AHI’s 2022 R&D tax incentive.[2]Other loans are unsecured and interest bearing.

Other Payables (Details) - Sche

Other Payables (Details) - Schedule of other payables - USD ($)	Dec. 31, 2022	Jun. 30, 2022
Schedule of Other Payables [Abstract]
Deferred acquisition consideration	$ 656,928

Issued Capital (Details) - Sche

Issued Capital (Details) - Schedule of issued capital - USD ($)	6 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
Schedule Of Issued Capital Abstract
Issued Capital Ordinary Share	196,053,969	166,749,382
Issued Capital Ordinary $	$ 71,803,404	$ 61,822,859

Issued Capital (Details) - Sc_2

Issued Capital (Details) - Schedule of ordinary share - USD ($)	6 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
Schedule Of Ordinary Share Abstract
At the start of the period Shares	166,749,382	136,362,538
At the start of the period $	$ 61,822,859	$ 39,213,794
Shares issued on exercise of Performance rights Shares	10,000,000	5,000,000
Shares issued on exercise of Performance rights $	$ 8,305,200	$ 1,996,500
Shares issued on exercise of Options Shares		3,103,622
Shares issued on exercise of Options $		$ 1,665,905
Shares issued to related party Shares		2,000,000
Shares issued to related party $		$ 920,000
Share based payments Shares		1,172,812
Share based payments $		$ 1,050,237
Share issue - NASDAQ IPO Shares		16,100,000
Share issue - NASDAQ IPO $		$ 16,706,786
Share issue - conversion of convertible note Shares		3,010,410
Share issue - conversion of convertible note $		$ 3,125,964
Share issue - Vertica acquisition Shares	1,500,000
Share issue - Vertica acquisition $	$ 180,000
Share issue - Wellteq acquisition Shares	17,804,587
Share issue - Wellteq acquisition $	$ 1,673,631
Less share issue costs Shares
Less share issue costs $	$ (178,286)	$ (2,856,327)
Total Shares	196,053,969	166,749,382
Total $	$ 71,803,404	$ 61,822,859

Reserves (Details) - Schedule o

Reserves (Details) - Schedule of reserves - USD ($)	Dec. 31, 2022	Jun. 30, 2022
Schedule Of Reserves [Abstract]
Equity Remuneration Reserve	$ 1,032,900	$ 9,338,100
Foreign currency reserve	7,347
Total reserve	$ 1,040,247	$ 9,338,100

Reserves (Details) - Schedule_2

Reserves (Details) - Schedule of equity compensation reserve - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2021
Schedule of Equity Compensation Reserve [Abstract]
Balance at the beginning of the year	$ 9,338,100	$ 5,293,019
Fair value vesting expense of options and performance rights		6,532,583
Fair value of options/performance rights exercised during the year	(8,305,200)	(2,487,502)
Balance at the end of the period	$ 1,032,900	$ 9,338,100

Reserves (Details) - Schedule_3

Reserves (Details) - Schedule of foreign currency reserve - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
Schedule of Foreign Currency Reserve [Abstract]
Balance at the beginning of the period
Movement in the value of foreign subsidiary losses and intercompany loan balances	7,347
Balance at the end of the period	$ 7,347

Commitments (Details)

Commitments (Details) - USD ($)	6 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
Commitments (Details) [Line Items]
Marketing costs	$ 200,000
WinScan platform description	AHI has the right to acquire up to 40% of Tinjoy’s Winscan Platform, priced at a valuation of US$10 million taking for consideration to be approximately US$2-4 million. This can be in cash or shares in AHI or a combination as mutually agreed.   ●12-24 month option to take up the 40% at AHI’s option to acquire a holding in WinScan. The option would be triggered should WinScan achieve user numbers of 5 million users a month. This would trigger a 20% investment of US$2 million from AHI. ●If WinScan achieves a user base of 10 million monthly users, AHI would be required to take up a 40% stake in WinScan at an agreed investment of US$4 million.     ●In the event AHI exercises its option, the US$200,000 marketing and training advance will form part of the total investment outlined above.     ●At the date of this report, US$50,000 in payments have been made to Tinjoy in lieu of AHI’s marketing contribution.
Paid amount	$ 150,000
Remaining balance	50,000
AHI [Member]
Commitments (Details) [Line Items]
Cash at subject to shareholder		$ 3,000,000
Amount of ordinary shares	$ 3,000,000

Events after the reporting pe_2

Events after the reporting period (Details) - USD ($)	1 Months Ended	6 Months Ended
	Jan. 23, 2023	Dec. 31, 2022	Dec. 31, 2021
Events after the reporting period (Details) [Line Items]
R&D Grant payment			$ 1,994,478
Short term loan facility	$ 1,000,000
Loan facility, interest rate		1.15%
Events After Reporting Period [Member]
Events after the reporting period (Details) [Line Items]
R&D Grant payment	$ 1,209,334
Loan facility, maturity date	Mar. 15, 2023
Loan facility, interest rate	15%
Repaid the lender	$ 400,000
Ordinary Shares [Member] | Events After Reporting Period [Member]
Events after the reporting period (Details) [Line Items]
Fully paid shares (in Shares)	500,000
Mr Peter Wall [Member] | Events After Reporting Period [Member]
Events after the reporting period (Details) [Line Items]
Loan facility	$ 1,000,000